Current Cancer Clinical Trials List

Cancer clinical trials lead to new treatments and cures. That’s why we do what we do every day.

Below is an up-to-date list of our cancer clinical trials currently underway. CAN focuses primarily on Phase II and Phase III trials, conducting further research on treatments that have already shown promise during Phase I trials. If you are a cancer patient interested in participating in a clinical trial, please visit our Patient section for more information.

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Disease Site: Gastrointestinal

Protocol Number: GI-002

Status: OPEN

Key Eligibility: Stage II or III; adenocarcinoma only; no metastatic disease; no prior invasive rectal malignancy

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Disease Site: Gastrointestinal

Protocol Number: GI-002

Status: OPEN

Key Eligibility: Stage II or III; adenocarcinoma only; no metastatic disease; no prior invasive rectal malignancy

ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

Disease Site: Breast

Protocol Number: A011106

Status: OPEN

Key Eligibility: invasive brca; no inflammatory brca; no HRT

A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)

Disease Site: Gastrointestinal

Protocol Number: C-13

Status: OPEN

Key Eligibility: High-risk, adenocarcinoma of colon; must have en bloc complete gross resection of tumor; no isolated, distant, or non-contiguous intra-abdominal mets; no prior history of colon or rectal ca

A disease registry for patients with chronic lymphocytic leukemia

Disease Site: Hematology

Protocol Number: informCLL

Status: OPEN

Key Eligibility: CLL/SLL; initiating tx w/I 30 days of enrollment w/novel therapies; no dx of b-cell malignancies other than CLL/SLL

A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung

Disease Site: Lung

Protocol Number: PrE0504

Status: OPEN

Key Eligibility: Unresectable stage IIIB or IV recurrent, squamous NSCLC; at least one prior platinum based tx; no previous MMAE containing agents

An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation chemotherapy.

Disease Site: Hematology

Protocol Number: CPKC412AUS56X – RADIUS X

Status: OPEN

Key Eligibility: Documented FLT3 mutataion (ITD or TKD); no prior AML therapy with a few exceptions

S1404 A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.

Disease Site: Melanoma

Protocol Number: S1404

Status: OPEN

Key Eligibility: Completely resected melanoma of cutaneous origin or of unknown primary; Stage IIIA (N2a), IIIB, IIIC, or Stage IV; melanoma of mucosal or other non-cutaneous origin ok; no ocular melanoma or brain mets

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma

Protocol Number: EA6141

Status: OPEN

Key Eligibility: Known BRAF; wild-type or mutated; prior adjuvant tx ok; no prior ipilimumab or PD-1/PD-L1 in adjuvant setting

S1404 A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Disease Site: Melanoma

Protocol Number: EA6134

Status: Pending IRB Approval

Key Eligibility: Unresectable stage III or IV disease; metastatic or unresectable, clearly progressive; BRAFV600E mutations; no previous CTLA4 or PD1 pathway blocking or BRAF/MEK inhibitor

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Disease Site: Breast

Protocol Number: NRG-BR003

Status: pT1-3; pN0, pN1, pN2a-b; pN3a-b, HER2-, ER/PgR-, no T4, no met disease

Key Eligibility: RADIATION THERAPY FACILITY INVENTORY FORM REQUIRED TO BE SENT TO CTSU PRIOR TO ENROLLMENT. PLEASE SEND COPY TO MVCC OFFICE ONCE COMPLETE

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)

Disease Site: Gastrointestinal

Protocol Number: RU021407I

Status: PENDING ACCRU ACTIVATION

Key Eligibility: Adenocarcinoma of colon or rectum; no previous regorafenib

Description: SOORI, DUNDER, BERG, AVERY, HUTCHINS, TILFORD, PETERSON, MIDATHADA, BLOCK, SU, HUYCK, LANGDON all non-approved physicians must enroll any eligible subjects through these physicians at the following locations: NCS (BERGAN, LEGACY, PAPILLION), HOC, SENCC, NHO.

Molecular Analysis for Therapy Choice (MATCH)

Protocol Number: EAY131

Status: OPEN

Key Eligibility: Solid tumor or lymphoma that has progressed following at least 1 line of standard therapy. Matching biopsy results to specific drug therapy

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)

Disease Site: Lung

Protocol Number: S1403

Status: OPEN

Key Eligibility: Stage IV or recurrent NSCLC; EGFR exon 19 deletion or exon 21 substitution mutation; tissue must be available to send out; no prior anticancer therapy for advanced or metastatic disease

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation

Disease Site: Brain

Protocol Number: A071102

Status: OPEN

Key Eligibility: Newly diagnosed grade IV; NO oligodendroglial features if 1p19q codeleted

Description: Imaging credentialing required by each site prior to enrollment

Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Neuropathy and Paclitaxel-induced Acute Pain Syndrome

Disease Site: Cancer Control

Protocol Number: RU221408I

Status: OPEN

Key Eligibility: Paclitaxel at a dose of 80 mg/m2 given, in the adjuvant setting every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Disease Site: Gastrointestinal

Protocol Number: S1406

Status: OPEN

Key Eligibility: Metastatic or locally advanced/unresectable colon or rectal adenocarcinoma; BRAF mutant status; 1-2 prior metastatic or locally advanced/unresectable systemic chemo regimens

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Disease Site: Lung

Protocol Number: A081105

Status: OPEN

Key Eligibility: Prev registration to A151216; EGF exon 19 deletion or L858R mutation; completely resected stage IB, II, or IIIA non-squamous w/neg margins

Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients with Node Positive Esophageal Cancer that Completed Pre-operative Therapy

Disease Site: Gastrointestinal

Protocol Number: RU021212I

Status: OPEN

Key Eligibility: Node positive (any T stage N1-3) proximal esophageal, distal esophagus or gastroesophageal (GE) junction adenocarcinoma after completing preoperative chemoradiation and surgery; No metastatic or recurrent disease; no R1 or R2 resection

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Disease Site: Lung

Protocol Number: E4512

Status: OPEN

Key Eligibility: Complete resection of stage IB, II, or IIIA NSCLC; registration to ALCHEMIST-SCREEN (A151216); Positive for translocation or inversion events involving the ALK gene locus

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib vs Placebo as Adjuvant Treatment in Patients with Germline BRCA ½ Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Disease Site: Breast

Protocol Number: B55

Status: OPEN

Key Eligibility: Non-metastatic triple negative; must have rcvd adjuvant therapy; documented BRCA 1 or 2 deleterious mutation; no prior PARP inhibitor

STUDY: ALLIANCE A031201 PHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER

Disease Site: Genitourinary

Protocol Number: A031201

Status: OPEN

Key Eligibility: Progressive CRPC; no prior taxane-based chemo for met disease; no prior antiandrogen or androgen synthesis inhibitor

A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Disease Site: Breast

Protocol Number: RU011201I

Status: OPEN

Key Eligibility: Stage IIIC or IV not amenable to local therapy; HER2-; no more than 1 prior therapy for advanced disease

Description: **THE FOLLOWING PHYSICIANS HAVE BEEN APPROVED TO ENROLL: SOORI, BLOCK, Berg, Peterson, Avery – all non-approved physicians must enroll any eligible subjects through these physicians at the following sites: NCS (BERGAN, LEGACY), NHO, SENCC

APHASE III, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF SORAFENIB IN DESMOID TUMORS OR AGGRESSIVE FIBROMATOSIS (DT/DF)

Disease Site: Carcinoid

Protocol Number: A091105

Status: OPEN

Key Eligibility: DT/DF; prev locoregional therapy; no sorafenib; no con tx w/CYP3A4 inhibitors or inducers

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Disease Site: Hematology

Protocol Number: E1A11

Status: OPEN

Key Eligibility: Symptomatic standard-risk multiple myeloma

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Disease Site: Breast

Protocol Number: S1207

Status: OPEN

Key Eligibility: ER/PR, HER-2 negative invasive breast carcinoma; no metastatic disease; high risk

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)(ENDURANCE)

Disease Site: Hematology

Protocol Number: S1211

Status: OPEN

Key Eligibility: Newly diagnosed, high risk, active MM; one prior cycle of chemo ok

A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma

Protocol Number: E3612

Status: OPEN

Key Eligibility: Untreated or prev recvd 1 tx for measurable, unresectable Stage III or IV melanoma

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Disease Site: Hematology

Protocol Number: E1412

Status: OPEN

Key Eligibility: Confirmed DLBCL expressing CD20 antigen; NO primary mediastinal large B-cell lymphoma; NO stage II-IV non-bulky disease

NSABP Patient Registry and Biospecimen Profiling Repository

Disease Site: Gastrointestinal

Protocol Number: MPR-1

Status: OPEN

Key Eligibility: Metastatic colorectal cancer; available block from primary tumor

A RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)

Disease Site: Lung

Protocol Number: R1306

Status: PRE-ACTIVATION

Key Eligibility: Newly diagnosed NSCLC; unresectable Stage IIIA or B disease

Description: RT CREDENTIALING REQUIRED PRIOR TO PARTICIPATION

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Disease Site: Gastrointestinal

Protocol Number: S0820

Status: OPEN

Key Eligibility: Stage 0-III; tx w/SOC w/resection alone or in combination w/adjuvant therapy

PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB (NSC # 737754, IND 75648) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS

Disease Site: Carcinoid

Protocol Number: A021202

Status: OPEN

Key Eligibility: low or intermediate grade neuroendocrine carcinoma; unresectable or met carcinoid in foregut, midgut, hindgut or other non-pancreatic site

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Disease Site: Breast

Protocol Number: E1Z11

Status: OPEN

Key Eligibility: Post-menopausal women; ER/PR + stage I-III adenocarcinoma of breast

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Disease Site: Hematology

Protocol Number: E3A06

Status: OPEN

Key Eligibility: Assymptomatic, high-risk, smoldering multiple myeloma

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Disease Site: Gastrointestinal

Protocol Number: E7208

Status: OPEN

Key Eligibility: Met or adv CRC, KRAS-wild type, first line tx with Oxaliplatin-containing chemo and Avastin. PD within 90 days of last Avastin.

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Disease Site: Lung

Protocol Number: C30610

Status: OPEN – Omaha sites only

Key Eligibility: SMALL CELL, Limited Stage

Description: OMAHA:Use Omaha IC
Not avail to Lincoln yet

Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Disease Site: Brain

Protocol Number: N0577

Status: OPEN

Key Eligibility: 1p/19q Co-deleted Anaplastic Glioma